

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): January 14, 2026

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-33137
(Commission File Number)

14-1902018
(I.R.S. Employer
Identification No.)

**300 Professional Drive,
Gaithersburg, Maryland 20879**
(Address of principal executive offices, including zip code)

(240) 631-3200
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

As previously announced, on January 14, 2026, Joseph C. Papa, president and chief executive officer of Emergent BioSolutions Inc., will present at the 44th Annual J.P. Morgan Healthcare Conference. Mr. Papa will present the slides furnished as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

<u>Exhibit No.</u>	<u>Description</u>
99.1	Emergent BioSolutions Inc. Investor Presentation, dated January 14, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 14, 2026

EMERGENT BIOSOLUTIONS INC.

By: /s/ RICHARD S. LINDAHL

Name: Richard S. Lindahl

Title: Executive Vice President, Chief Financial Officer

Combating Public Health Threats for Communities Around the World

44th Annual J.P. Morgan Healthcare Conference

Joe Papa
President and Chief Executive Officer

January 14, 2026



Safe Harbor Statement/Trademarks

EMERGENT

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future investments and business development opportunities, future financial position, future revenues and earnings, future leverage ratios, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "can" "continue," "could," "estimate," "expect," "confident," "commit," "forecast," "future," "outlook," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, and ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CNJ-016® (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), BAT® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), BioThrax® (Anthrax Vaccine Adsorbed) Ebanga™ (ansuvimab-zykl) and/or TEMBEKA® among others, as well as contracts related to development of medical countermeasures; our ability to meet our commitments to quality and compliance in all of our manufacturing operations; our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring; the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN® (naloxone HCl) Nasal Spray and over-the-counter NARCAN® Nasal Spray; our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries; the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations; our ability to negotiate new or further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing related to our Bioservices and under existing Bioservices contracts; our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers; the results of pending government investigations and their potential impact on our business; our ability to satisfy the conditions of our litigation settlement agreements, and the potential impact of such agreements, including the funds to resolve the related litigation, on our business; our ability to comply with the operating and financial covenants required by (i) our term loan facility under a credit agreement, dated August 30, 2024, among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent, (ii) our revolving credit facility under a credit agreement, dated September 30, 2024, among the Company, certain subsidiary borrowers, the lenders from time to time party thereto and Wells Fargo, National Association, as Agent, and (iii) our 3.875% Senior Unsecured Notes due 2028; our ability to maintain adequate internal control over financial reporting and to prepare accurate financial statements in a timely manner; our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future; our ability to invest in our business operations as a result of our current indebtedness; the impact of our share and debt repurchase programs; the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to United States Food and Drug Administration marketing authorization, and corresponding procurement by government entities outside the United States; our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic, the sale of our Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc., a subsidiary of Bora Pharmaceuticals Co., Ltd., the sale of RSDL® to BTG International Inc., a subsidiary of SERB Pharmaceuticals and the sale of our Baltimore-Bayview drug substance manufacturing facility to Syngene International, and any other divestitures or restructuring activities; the success of our commercialization, marketing and manufacturing capabilities and strategy; our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria; our ability to attract and retain qualified personnel; our ability to adequately secure and protect our intellectual property rights; the impact of cybersecurity incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; and the accuracy of our estimates regarding future revenues, expenses, capital requirements and need for additional financing. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ materially from our expectations in any forward-looking statement. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Company Overview



We Help Prepare for Today's Health Challenges and Tomorrow's Threats*

Our mission is **to protect and save lives.**

\$775 - \$835M

2025 Revenue Guidance

11

Products

11

Biodefense/MCM Contract Mods & Product Orders YTD

900+

Employees

Global Strategic Partner
to governments, NGOs and
biopharma innovators

Naloxone Market
Leadership

*Previously reported Company data, as of 10/29/25

Experienced and Trusted Management Team



Joseph Papa
President and CEO



Richard Lindahl
EVP, Chief Financial Officer



Coleen Glessner
EVP, Quality, Ethics
and Compliance



Simon Lowry, M.D.
Chief Medical Officer, Head of
Research and Development



Jessica Perl
SVP, General Counsel and
Corporate Secretary



Stephanie Duatschek
SVP, Chief Global Strategy &
Franchise Development Officer



Michelle Pepin
SVP, Chief Human
Resources Officer




Bill Hartzel
SVP, Manufacturing
and Bioservices



Paul Williams
SVP, Products Business
& Gov't Affairs

Multi-Year Transformation Plan to Create Shareholder Value



Most Diverse Biodefense/Medical Countermeasures and Naloxone Portfolio Globally¹

- 25+ years of experience developing and manufacturing protections against critical public health threats
- Deep experience working with the U.S. and allied governments to meet some of their most significant preparedness needs
- Continued investment in biodefense/MCM capabilities to remain ready to fulfill the needs of the U.S. in protecting the public and the warfighter



¹) Supporting data is on file with the company.

*Ebanga™ is a trademark of RIDGEBACK BIOTHERAPEUTICS L.P.

**KLOXXADO® is a registered trademark of Hikma Pharmaceuticals USA Inc.

Learn more about Emergent products and access prescribing information [here](#)

Biothreats: America's Growing Security Risk

New survey of 250+ policy opinion leaders reinforces significant risk of bioterrorism across U.S.¹



1. Penta Group surveyed 252 policy opinion leaders between October 10, 2025 - October 16, 2025. The survey was designed to include a nationally representative sample; results from the survey have a sampling margin of error of +/-6.1 percentage points and represent a mix of demographics such as age, gender, region, and income. Data on file.


Expanding the Presence of Our MCM Products in an Increasingly Dangerous World

North America/U.S. Centric manufacturing for biodefense with additional capacity opportunities

- Lansing, MI
- Winnipeg, Canada (NEW: now FDA-approved facility as the drug product manufacturing and testing site for raxibacumab)
- Rockville, MD
- Bayview, MD (capacity reservation w/ divestiture partner)
- Canton, MA

Current markets; also, key markets of interest for MCM products outside North America

All EBS MCM products are USMCA-compliant



MCM Business: Supporting U.S. and International Governments' Biodefense Readiness and Supply Resilience

Consistent and ongoing engagement with U.S. and international governments



Global Strategic Partner to governments, NGOs
and biopharma innovators

**International orders represent 34% of total
MCM revenues in the first nine months ending
Sept 30, 2025***

11 U.S. Biodefense/MCM Contract
Modifications & Product Orders*

No disruptions during USG shut down

*Previously reported Company data, as of 10/29/25

Heightened Efforts to Combat the Opioid Overdose Epidemic

President Trump signed an Executive Order (Dec. 2025) designating illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction.

CDC prelim data predicts 76,516 drug overdose deaths (8 in 10 are caused by an opioid) for the 12 months ending in April 2025. This is a 24.5% decline in U.S. overdose deaths compared to the previous year.¹



PHAC data shows Canadian opioid deaths at lowest observed level since 2020 and down 22% YoY.²



A naloxone vending machine at UM Health-West Community Clinic, pictured Aug. 12, 2025.

1. <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
2. <https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/>

Naloxone Business: Leading With Purpose to Help Save Lives

NEW: FDA approves OTC NARCAN® Nasal Spray to be packaged in new carrying case—a unique option/solution to increase accessibility—COMING SOON!

- While many factors are driving the reduction in opioid overdose deaths since 2023-2024, third-party sources have associated the timing and introduction of OTC NARCAN® Nasal Spray with this decline¹
- Market-leading offerings, e.g. NARCANDirect®, continue to command differentiated capabilities; platform now features KLOXXADO® Nasal Spray 8 mg, Wall Units and Convenience Kits
- Continuing to invest in solutions to drive access, as well awareness initiatives
- Continued partnership with National Safety Council (NSC); received the NSC Green Cross Advocate for Safety Award, alongside Amazon
- Received Corporate Hero Award from Victoria's Voice Foundation
- \$50+B in total reported opioid settlement dollars; ongoing support from Federal and State support programs

1. Washington Post, Opinion | Purdue Pharma's \$7.4 billion settlement should go toward Narcan



Multiple Growth Opportunities Ahead

We plan to invest to enable sustainable, long-term growth.

Exploring potential for government-funded R&D development programs.

Selectively evaluating strategically suitable external programs.

In 2025, completed Rocketvax investment & pursuit of strategic relationship	Canada exclusive commercial rights; additional line extensions for naloxone business
---	--

Expanding U.S.
& international
MCM orders and
opportunities
(ongoing)

Strong cash & liquidity position enables additional internal programs and external business development opportunities (ongoing)

Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Development Opportunities

Product/Candidate	Disease Area	Partner(s)	Stage of Development						
			Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Submission	Approved
Ebanga™*	Zaire ebolavirus	BARDA							✓
TEMBEKA®	Smallpox	BARDA							✓
	Mpox	PANTHER, Africa CDC-led				➡	**		
raxibacumab	Anthrax	BARDA							✓
CDC Category A Agent	Undisclosed	Undisclosed partner		➡					
CDC Category B Agent	Undisclosed	Undisclosed partner		➡					
Pandemic Flu Vaccine	Flu vaccine candidate/platform to address pandemic flu	TBD candidate/partner selection	➡						

■ Current Portfolio ■ Active/Work Underway ■ Discovery-Evaluation

*EbangaTM is a trademark of RIDGEBACK BIOOTHERAPEUTICS L.P.

**PANTHER, Africa CDC-led non-registrational study, "Mpox Study in Africa" (MOSA)



Financials



Improved Operating Efficiency Driving Increased Profitability & Cash Generation

(YTD as of 9/30/25) (\$ in millions)

EMERGENT



1. See "End Notes: Non-GAAP Financial Measures" and "Appendix of 10/29/25 earnings call materials" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures.
 2. 2024 Total Revenues includes revenue related to the RSDL® product and Camden Facility, which were sold in Q3 2024 and no longer contributing ~\$65M Total Revenues in 2025.


\$100M Term Loan Paydown on December 29, 2025

Gross Debt of \$593M, (\$275M) or (32%) versus year end 2023

Net Debt of \$448M (\$309M) or (41%) versus year end 2023

EMERGENT

- ✓ Used existing Balance Sheet Cash on December 29th to paydown \$100M of Term Loan Principal
- ✓ Net Leverage remains at 2.1x, down significantly from prior periods
- ✓ Maintaining strong cash position for future capital allocation initiatives




Targeting a Net Leverage Ratio of 2.0x – 3.0x Adjusted EBITDA going forward¹

1. Excludes potential acquisitions and represents current core business structure

17

Capital Allocation Priorities During 2026 Turnaround Period

(YTD as of 9/30/25)



1. See "End Notes: Non-GAAP Financial Measures" and "Appendix of 10/29/25 earnings call materials" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures.

FY 2025 Revenue & Profitability Guidance, as of 10/29/25

METRIC (\$ in millions)	FY 2025 as of October 29, 2025	FY 2025 as of August 6, 2025	FY 2025 as of May 7, 2025	FY 2025 as of March 3, 2025
Total revenues	\$775 - \$835 	\$765 - \$835	\$750 - \$850	\$750 - \$850
Net income	\$60 - \$75 	\$40 - \$65	\$20 - \$70	\$16 - \$66
Adjusted net income¹	\$70 - \$85 	\$45 - \$70	\$20 - \$70	\$20 - \$70
Adjusted EBITDA¹	\$195 - \$210 	\$175 - \$200	\$150 - \$200	\$150 - \$200
Adjusted gross margin %¹	52% - 54% 	50% - 52%	48% - 51%	48% - 51%
Segment Level Revenue MCM Products²	\$450 - \$475 	\$440 - \$475	\$435 - \$485	\$435 - \$485
Segment Level Revenue Commercial Products³	\$265 - \$300 	\$265 - \$300	\$265 - \$315	\$265 - \$315
Key Assumptions (\$ and shares in millions)				
Interest expense	\$55			
R&D	~7% to 8% of Revenues			
SG&A	~25% to 26% of Revenues			
Weighted avg. fully diluted share count	~56			
Capex	~\$16			
Depreciation & amortization	~\$100			

1. See "End Notes: Non-GAAP Financial Measures" and "Appendix of 10/29/25 earnings call materials" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures.

2. Our MCM Products forecast excludes revenues related to RSDL®, which product was sold during the third quarter of 2024.

3. Our Commercial Products forecast consists of revenues for NARCAN® Nasal Spray and revenues from distribution of KLOXXADO® Nasal Spray 8 mg pursuant to an agreement with Hikma Pharmaceuticals PLC in January 2025.

Summary

- **On track with turnaround phase of multi-year plan**
- **Reduced debt by \$100M in December 2025** with continued focus on capital allocation strategies to drive value for stakeholders
- **Increased gross margin & profit follow through from 2024**, generated through restructuring actions and improved utilization across manufacturing network
- Executing on key turnaround actions **to drive our business forward**
 - Strong performance for naloxone business; launched new solutions
 - Continue to meet U.S. government expectations for MCM preparedness efforts; ongoing international engagement
- **Pursuing organic and inorganic growth initiatives** and creating shareholder value
- Ongoing commitment to the **highest standards of patient safety, quality and compliance** across the enterprise

EMERGENT



EMERGENT®

EMERGENT®

www.emergentbiosolutions.com